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Abstract
Background: Glucocorticoids influence the synthesis and metabolism of catecholamines (epinephrine and norepinephrine)
and metanephrines (metanephrine and normetanephrine). The aim of this study was to measure urinary catecholamines
and metanephrines in dogs with hypercortisolism before and during trilostane therapy.
Urine samples were collected during initial work up and during therapy with trilostane in 14 dogs with hypercortisolism and
in 25 healthy dogs. Epinephrine, norepinephrine, metanephrine and normetanephrine were measured using high-pressure
liquid chromatography and expressed as ratios to urinary creatinine concentration.
Results: Untreated dogs with hypercortisolism had significantly higher epinephrine, norepinephrine, and normetanephrine:
creatinine ratios compared to healthy dogs. During trilostane therapy, urinary catecholamines and their metabolites did not
decrease significantly. However, dogs with low post-ACTH cortisol concentrations during trilostane therapy had less
increased epinephrine, norepinephrine and normetanephrine:creatinine ratios compared to healthy dogs. There was
no correlation of urinary catecholamines and their metabolites with baseline or post-ACTH cortisol or endogenous
ACTH concentrations during trilostane therapy.
Conclusion: Influences between steroid hormones and catecholamines seem to occur, as dogs with hypercortisolism
have significantly higher urinary epinephrine, norepinephrine, and normetanephrine:creatinine ratios. Once-daily trilostane
therapy does not lead to a significant decrease in catecholamines and their metabolites. Trilostane-treated dogs still have
increased urinary epinephrine, norepinephrine and normetanephrine:creatinine ratios during trilostane therapy.
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Background
Catecholamines (epinephrine, norepinephrine) are produced
by the chromaffin cells of the adrenal medulla and the post-
ganglionic fibers of the sympathetic nervous system. They
are synthesized from the amino acid tyrosine, which is
converted to L-dihydroxyphenylalanine (L-DOPA), next to
dopamine and finally to norepinephrine [1]. In most
sympathetic postganglionic neurons, norepinephrine is the
final product. In the cells of the adrenal medulla,
norepinephrine is further converted into epinephrine [1].
After release into the plasma, catecholamines are quickly
metabolized. Metabolism takes place mainly in the adrenal
gland cells and only a small proportion in the liver and
kidneys and includes the conversion of epinephrine to
metanephrine and norepinephrine to normetanephrine [2].
While catecholamines are released intermittently, metane-
phrines (metanephrine and normetanephrine) are constantly
released into the circulation and excreted in the urine [2].
This constant liberation explains why measurement of
urinary or plasma metanephrines has a higher accuracy to
diagnose pheochromocytoma than the measurement of
catecholamines [2].
The adrenal medulla comprises about one-fourth of
the adrenal mass. The rest of the adrenal mass consists
of the adrenal cortex containing steroid-producing adre-
nocortical cells. For a long time, the two cell populations
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within the adrenal gland were considered as two inde-
pendent endocrine systems. However, nowadays, interac-
tions between steroid hormones and catecholamines are
well known. Glucocorticoids have been shown to influ-
ence several enzymes involved in catecholamine synthe-
sis and metabolism: first, tyrosine hydroxylase, which is
the rate-limiting enzyme in catecholamine biosynthesis;
second, PNMT (Phenylethanolamin-N-Methyltransfer-
ase), which converts norepinephrine to epinephrine; and
third, dopamine β-hydroxylase, which hydroxylates
dopamine to norepinephrine [3–7]. In vitro, glucocorti-
coids have been shown to increase the release of cate-
cholamines from canine adrenal glands [8]. Therefore, it
was not surprising that dogs with hypercortisolism (HC)
were found to have increased concentrations of urinary
epinephrine-, norepinephrine- and normetanephrine-to-
creatinine ratios compared to healthy dogs [9]. However,
the evolution of urinary catecholamines and metane-
phrines concentrations during the therapy of canine HC
is unknown. Hypercortisolism is an important differen-
tial diagnosis in dogs with pheochromocytomas, as
clinical signs of both diseases overlap and pheochromo-
cytomas cannot be distinguished ultrasonographically
from tumors of the adrenal cortex.
Therefore, the objective of this study was to evaluate
urine concentrations of catecholamines and metane-
phrines in dogs with HC before and during therapy with
trilostane. We hypothesized that successful therapy of
HC with trilostane would lead to a significant decrease
in urinary epinephrine, norepinephrine, metanephrine
and normetanephrine:creatinine ratios due to the
cortisol-lowering effect of trilostane.
Methods
Animals
Fourteen dogs with naturally occurring hypercortisolism
(HC) were prospectively enrolled. Results of catechol-
amines and metanephrines:creatinine ratios before trilos-
tane therapy of five dogs had been previously reported
as part of a former study [10]. Nine dogs were male (4
castrated) and five dogs female (4 spayed). Breeds in-
cluded Dachshund (1), Giant Schnauzer (1), Nova Scotia
Duck Tolling Retriever (1), Parson Jack Russell Terrier
(1), Petit Bleu de Gascogne (1), Tibetan Terrier (1),
Yorkshire Terrier (1), and 7 mixed-breed dogs. Age
ranged between 6 and 14 years (median 8.5; standard
error of mean (SEM): 0.6) and body weight between 7
and 58 kg (median 18.8; SEM: 3.7). Criteria for inclusion
were the presence of clinical signs consistent with HC
(e.g. polyuria, polydipsia, polyphagia, panting, skin signs,
weakness, abdominal enlargement), a low-dose dexa-
methasone suppression test (LDDS test) or ACTH
stimulation test results compatible with HC and the
owner’s agreement to treat and regularly re-evaluate the
dog over at least a 6-month period [9, 11]. Pituitary-
dependent hypercortisolism (PDH) was diagnosed in all
dogs by means of a normal or increased concentration
of endogenous ACTH, bilateral symmetrical appearance
of the adrenal gland determined by ultrasonography
and/or demonstration of pituitary enlargement by com-
puted tomography.
Twenty-five client-owned dogs were enrolled as con-
trols. These dogs had been part of previous studies [9,
10, 12]. Eleven dogs were male (6 castrated) and 14
female (12 spayed), and breeds included Australian
Shepherd (1), Berger Blanc Suisse (1), Bernese Mountain
Dogs (2), Border Collie (1), Golden Retriever (2),
Gordon Setters (2), Labrador Retriever (2), Nova Scotia
Duck Tolling Retriever (1), Rhodesian Ridgeback (1),
Siberian Huskies (2), Standard Poodle (1), Tervueren (1),
and eight mixed-breed dogs. Age ranged between 2 and
15 years (median 7; SEM: 0.6) and body weight between
10.4 and 59.2 kg (median 26; SEM: 2.3). The dogs were
considered as healthy, based on detailed information
provided by their owners and the results of a physical
examination, CBC, serum biochemistry profile, and
urinalysis. The inclusion of the dogs in the study was
approved by the veterinary office of the canton of Zurich
and was in accordance with the guidelines and directives
established by the Animal Welfare Act of Switzerland
(TVB 199/2004).
Sample collecting and processing
All urine samples (healthy and sick dogs) used for analysis
of catecholamines, metanephrines and creatinine were
taken in hospital, either by free catch or by cystocentesis.
In dogs with HC the first sample was taken in the morn-
ing during the initial work up for HC and once during
trilostane therapy (at least 6 months after start of trilos-
tane therapy). During trilostane therapy the urine was col-
lected 2-3 h after the dose of trilostane in the morning.
Urine collection and processing was done as reported pre-
viously [9, 12, 13]. Briefly, 10 ml of urine were placed in a
silicone-coated tube containing 270-280 μL of 20% hydro-
chloric acid (HCl). Urinary pH was measured using pH
indicator strips (range of pH 1 – 6) and HCl was added to
achieve a pH ≤ 2 if needed. Samples were light protected
and stored at −20 °C until analysis.
Measurement of Catecholamines and Metanephrines
Urine samples were analysed at the Institute of Clinical
Chemistry, University Hospital Zurich, Zurich,
Switzerland as previously described [9, 12, 13]. Urinary
epinephrine, norepinephrine, total metanephrine and
total normetanephrine were quantified by High Pressure
Liquid Chromatography with amperometric detection as
separate compounds. The terms “catecholamines” or
“metanephrines” (plural form) includes epinephrine and
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norepinephrine or normetanephrine and metanephrine,
respectively. The results were expressed as a ratio to
urinary creatinine concentrations and will be listed in
the following sections as: norepinephrine:creatinine,
epinephrine:creatinine, normetanephrine:creatinine and
metanephrine:creatinine.
Measurement of cortisol and endogenous ACTH
For the ACTH stimulation test, blood samples were
taken before, and 60 min after, intravenous injection of
5 μg/kg synthetic tetracosactide (Synacthen®, Novartis
Pharma Schweiz AG, Bern, Switzerland). Cortisol
concentrations were measured by chemiluminescence
assay (DPC Immulite® 1000, Siemens Schweiz AG,
Zurich, Switzerland). The intra-assay coefficients of vari-
ation were 10% and 6.3% at cortisol levels of 74.5 and
521 nmol/L, respectively. The sensitivity of the assay
was 5.5 nmol/L. Endogenous ACTH before ACTH
stimulation was determined by a chemiluminescence
assay (DPC Immulite® 1000, Siemens Schweiz AG,
Zurich, Switzerland) previously validated for dogs [14, 15].
Blood was collected into chilled EDTA-coated tubes
placed on ice and centrifuged at 4 °C. Cortisol and
endogenous ACTH measurements were performed in
house twice a week; plasma was stored either at −20 °C
(cortisol) or at −80 °C (ACTH) until assayed.
Experimental design
The prospective study was performed between May
2006 and October 2014 at our hospital. The initial dose
of trilostane for dogs with HC was 1-2 mg/kg q 24 h (in
the morning). ACTH stimulation tests were performed
prior to trilostane treatment (except for 1 dog) and at
regular intervals thereafter (2, 4, 8, 12 and 16 weeks).
The test was performed 2-3 h after the daily dose of tri-
lostane according to the previously described treatment
protocol [16]. The treatment goal was to achieve a post-
ACTH cortisol concentration of 41-138 nmol/L. The
dose of trilostane was adjusted in dogs with post-ACTH
serum cortisol >138 nmol/L or <41 nmol/L and clinical
signs suggestive of hypercortisolism (polyuria, polydip-
sia, polyphagia) or hypocortisolism (reduced appetite,
vomiting or nausea, soft feces), respectively.
Urine samples for determination of catecholamines
and metanephrines were collected at diagnosis of HC
and at least 6 months after starting trilostane therapy
(ensuring that all dogs were clinically controlled for at
least 2 months). At the re-evaluation during trilostane
therapy, dogs had to be clinically controlled (polyuria,
polydipsia and panting decreased, weakness and agility
increased), owners had to be satisfied with the treatment
outcome and post-ACTH cortisol concentrations had to
be <138 nmol/L. Median time for urinary sample
collection during trilostane therapy was 11 months
(range: 6-40 months) after diagnosis.
Statistical analysis
Data were analyzed with non-parametric statistical methods
(GraphPad Prism6, Graph Pad Software, San Diego, CA,
USA, SPSS 22.0 for Windows, SPSS Inc., Chicago, IL USA).
Ranges and median values are reported. The Wilcoxon
signed rank test was used for comparisons between differ-
ent time points, and the Mann-Whitney U-Test for com-
parisons between different groups. Linear correlations were
calculated by Spearman’s non-parametric correlation.
Values of p < 0.05 were considered significant.
Preliminary reference intervals for the urinary catechol-
amines and metanephrines were generated by the nonpara-
metric method of percentile estimates with confidence
intervals to determine the central 95th percentile interval
(i.e. 2.5 through 97.5th percentile range) for results from
clinically normal dogs [17]. Reference intervals thus
determined were: epinephrine: creatinine = 1-18; norepin-
ephrine: creatinine = 1-19; metanephrine: creatinine = 12-
255; normetanephrine: creatinine = 14-123.
Results
Catecholamines and metanephrines before and during
therapy
Concentrations of catecholamines and metanephrines for
dogs with HC before and during trilostane therapy and for
healthy dogs are depicted in Fig. 1 and Table 1. In one dog
the metanephrine:creatinine ratio could not be measured
during trilostane therapy due to a chemical artefact.
The epinephrine, norepinephrine, and normetanephri-
ne:creatinine ratios before trilostane therapy and the
norepinephrine and normetanephrine:creatinine ratios
during trilostane therapy of dogs with HC were signifi-
cantly higher than those of healthy dogs (before:
p < 0.01, < 0.01, < 0.0001, respectively; during: p < 0.01,
< 0.001, respectively) (Fig. 1).
There was no significant decrease in the epinephrine,
norepinephrine, metanephrine and normetanephrine:-
creatinine ratios of dogs with HC during trilostane ther-
apy (p = 0.1, 0.8, 0.2, 1, respectively) (Fig. 1).
Grouping dogs according to their post-ACTH cortisol
concentration during trilostane therapy, revealed 9 dogs
with post-ACTH cortisol between 41 and 138 nmol/L
(group 1) and 5 with post-ACTH cortisol <41 nmol/L
(group 2, no clinical signs of hypocortisolism evident).
Concentrations of catecholamines and metanephrines
for both groups during trilostane therapy and for healthy
dogs are depicted in Fig. 2 and Table 2.
There was no significant difference in the epinephrine,
norepinephrine, metanephrine and normetanephrine:-
creatinine ratios between the two groups during therapy
(p = 0.3, 0.6, 0.6, 0.3, respectively) (Fig. 2). Likewise
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epinephrine, norepinephrine, metanephrine and norme-
tanephrine:creatinine ratios did not decrease significantly
during treatment in both groups (group 1: p = 0.3, 0.7,
0.5, 0.6, respectively; group 2: p = 0.6, 0.5, 0.6, 0.6, re-
spectively). Compared to healthy dogs, however, dogs
with post-ACTH cortisol between 41 and 138 nmol/L
still had significantly increased epinephrine, norepineph-
rine and normetanephrine:creatinine ratios (p < 0.05,
< 0.01, < 0.001, respectively), whereas in dogs with
post-ACTH cortisol <41 nmol/L these differences were di-
minished (p = 0.9, 0.2, 0.07, respectively) (Fig. 2).
There was no significant correlation of epinephrine, nor-
epinephrine, metanephrine or normetanephrine:creatinine
ratios with baseline or post-ACTH-stimulated cortisol or
with endogenous ACTH concentrations (n = 6) during tri-
lostane therapy (Table 3).
Discussion
As expected, some dogs with HC had increased urinary cat-
echolamines and metanephrines. This is in agreement with
results from previous studies, which showed that in up to
50% of dogs with HC urinary epinephrine, norepinephrine
and normetanephrine:creatinine ratios are above those of
control dogs [9, 10]. These findings most likely reflect the
increased catecholamines synthesis (epinephrine and nor-
epinephrine) and metabolism (conversion into metanephr-
ine and normetanephrine) induced by glucocorticoids [3–7].
Unexpectedly, urinary catecholamines and metane-
phrines did not decrease significantly during trilostane
therapy in dogs with HC, and thus contradicted our
hypothesis. There are several possible explanations for this
finding. After once-daily trilostane administration cortisol
concentrations are unlikely to be reduced over a 24-h
period. Trilostane is an orally administered competitive
inhibitor of the 3β-hydroxysteroid dehydrogenase, which
mediates the conversion of pregnenolone to progesterone
in the adrenal glands [18]. Cortisol, aldosterone and
androstenedione are produced from progesterone via dif-
ferent biochemical pathways. Trilostane inhibits the
production of progesterone and therefore the synthesis of
its end products [19]. It is known that the maximum in-
hibitory effect of trilostane on glucocorticoid production
in dogs is reached 2-4 h after its administration, and that
cortisol concentrations re-increase thereafter [20]. In the
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Fig. 1 Urinary epinephrine (a), norepinephrine (b), metanephrine (c) and normetanephrine:creatinine (d) in dogs with hypercortisolism before
(open circles) and during (closed circles) trilostane therapy and in healthy dogs (squares). The horizontal bars represent the median of each group.
The shaded area indicates the preliminary reference interval
Table 1 Ranges (median/SEM) of urinary catecholamines and
metanephrines to creatinine ratios in dog with hypercortisolism
(HC) before and during trilostane therapy and in healthy dogs
Parameters Dogs with HC Healthy dogs
before therapy during therapy
Epinephrine:
creatinine
1-25a
(8 / 2.1)
0.5-19
(6 / 1.7)
1-18
(2 / 0.7)
Norepinephrine:
creatinine
6-40a
(11 / 2.9)
4-36a
(9.5 / 3.2)
1-19
(6 / 0.9)
Metanephrine:
creatinine
25-145
(70.5 / 10.4)
20-165
(45 / 14.9)
12-255
(58 / 12.3)
Normetanephrine:
creatinine
51-300a
(97 / 23.4)
47-345a
(148 / 29.9)
14-123
(51 / 4.8)
asignificant difference compared to healthy dogs
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present study trilostane was dosed once-daily. Twice-daily
therapy would lead to a more pronounced decrease in
catecholamines and metanephrines concentrations than
once-daily therapy, but this hypothesis has to be deter-
mined in a future study. Supporting evidence for this
hypothesis is that dogs with low post-ACTH cortisol con-
centration (< 41 nmol/L) had a diminished increase in epi-
nephrine, norepinephrine and normetanephrine:creatinine
ratios compared to healthy dogs. In contrast, the increase
in epinephrine, norepinephrine and normetanephrine:-
creatinine ratios persisted in the dogs with post-ACTH
cortisol between 41 and 138 nmol/L.
Cortisol secretion during trilostane treatment has been
evaluated in a study by Galac et al., where the authors
compared urinary corticoid to creatinine ratios (UCCRs)
in dogs with PDH before and during trilostane treatment
after several months of optimal dosing of trilostane [21].
In that study, although UCCRs decreased significantly
during therapy, they did not decrease below the upper
limit of the reference range in the majority of the dogs,
which might suggest that the influence of cortisol on the
body system in trilostane-treated dogs persists, even in
controlled dogs. Another interesting result in their study
was that during long-term follow-up, a decrease in the
UCCR below the upper limit of the reference range was
associated with hypocortisolism. This seems similar
to our results, where, as mentioned above, only dogs
with a post-ACTH cortisol <41 nmol/L had urinary
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Fig. 2 Urinary epinephrine (a), norepinephrine (b), metanephrine (c) and normetanephrine:creatinine (d) in dogs with hypercortisolism during
trilostane therapy according to their post-ACTH cortisol concentration (41-138 nmol/L or <41 nmol/L). The horizontal bars represent the median
of each group. The shaded area indicates the preliminary reference interval
Table 2 Ranges (median/SEM) of urinary catecholamines and
metanephrines to creatinine ratios in dog during trilostane
therapy with post-ACTH cortisol between 41 and 138 nmol/L
(group 1) and <41 nmol/L (group 2) and in healthy dogs
Parameters Dogs with HC Healthy dogs
Group 1 Group 2
Epinephrine:creatinine 0.5-19a
(7 / 1.8)
1-19
(2 / 3.4)
1-18
(2 / 0.7)
Norepinephrine:creatinine 4-36a
(10 / 4.1)
4-35
(9 / 5.6)
1-19
(6 / 0.9)
Metanephrine:creatinine 20-163
(59 / 19)
25-165
(37 / 26.2)
12-255
(58 / 12.3)
Normetanephrine:creatinine 54-345a
(229 / 36.3)
47-335
(80 / 55)
14-123
(51 / 4.8)
asignificant difference compared to healthy dogs
Table 3 Correlations between urinary catecholamines and
metanephrines with cortisol and endogenous ACTH
concentrations during trilostane therapy
Parameter Spearman correlation coefficient / p-value
Baseline
cortisol
Post-ACTH
cortisol
Endogenous ACTH
Epinephrine:
creatinine
0.01 / 1 0.5 / 0.05 0.2 / 0.7
Norepinephrine:
creatinine
−0.18 / 0.5 0.4 / 0.2 −0.1 / 0.8
Metanephrine:
creatinine
0.06 / 0.9 0.5 / 0.1 −0.2 / 0.7
Normetanephrine:
creatinine
0.16 / 0.6 0.4 / 0.2 −0.8 / 0.06
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catecholamines and metenaphrines comparable to those
of healthy dogs.
Another explanation for the failure to demonstrate a
reduction in urinary catecholamines and metanephrines
during trilostane therapy might be related to the blood
supply of the adrenal medulla. The adrenal medulla gets
its main blood supply through the capillaries of the cor-
tex via the cortical-medullary portal system [1]. Due to
this vascular system, the adrenal medulla gets in contact
with glucocorticoids. In dogs with HC, even though
controlled during trilostane therapy, the glucocorticoid
concentration, which reaches the adrenal medulla
through the portal system, is probably still much higher
than under physiologic conditions.
Plasma free catecholamines and metanephrines or urin-
ary catecholamines and metanephrines:creatinine ratios
are used to diagnose canine pheochromocytomas [22].
Clinical signs usually result from secretion of excessive
amounts of catecholamines, and only rarely from the
space-occupying or invasive nature of the tumor [23–29].
Hypercortisolism is one of the most important differential
diagnoses of pheochromocytoma. Both diseases may have
similar clinical signs (weakness, polyuria, polydipsia, pant-
ing) as well as similar ultrasonographic features; in rare
cases they can even occur concurrently [10]. In dogs,
measurement of plasma free normetanephrine and urinary
normetanephrine:creatinine ratio have been shown to be
the most reliable biochemical test for diagnosing pheo-
chromocytoma, even in cases in which the two diseases
occur concurrently [9, 10, 13, 30]. Metanephrine to
creatinine ratios were also significantly higher in dogs with
pheochromocytoma compared to those of dogs with HC,
but a considerable overlap existed [10]. This is similar to
results described in human medicine, where normeta-
nephrine concentrations have the highest sensitivity and
specificity in diagnosing pheochromocytoma [31, 32].
Most likely, this reflects the fact that the vast majority of
human and canine pheochromocytomas predominantly
produce norepinephrine, which is metabolized to norme-
tanephrine [10, 30, 31, 33]. Our study shows that dogs
with HC treated with once-daily trilostane still have in-
creased urinary concentrations of catecholamines and
metanephrines and that diagnosing pheochromocytoma in
these dogs might be challenging.
A limitation of the study is its rather low sample size.
Another potential limitation is the lack of histopathology to
exclude concurrent pheochromocytoma. However, only
post mortem histopathology would reliably exclude concur-
rent pheochromocytoma, which is difficult to obtain in a
clinical setting with medically treated patients. To minimize
the risk of concurrent pheochromocytoma, we included
only dogs with no obvious adrenal mass and with good
clinical control after 6 months of trilostane therapy. Even
though all dogs included seemed clinically well controlled,
some dogs might have been overdosed according to their
post-ACTH cortisol value (< 41 nmol/L). This lack of a
proven gold standard test is another limitation of studies
evaluating dogs during trilostane therapy.
Conclusions
Although dogs with HC can be controlled during once-
daily trilostane therapy, it is likely that urinary concen-
trations of catecholamines and metanephrines remain
increased, reflecting a constant influence of the
endogenously increased cortisol concentration in these
dogs.
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